Abstract:Background: Improving the aggregation and penetration in tumor sites increases the anti-tumor efficacy of nanomedicine. In the current study, we designed cyclodextrin modified PLGA nanoparticles loaded with paclitaxel to elevate the accumulation and prolong circulation of chemotherapy drugs in vivo. Methods: The PLGA nanoparticles loaded with paclitaxel (PTX PLGA NPs) and cyclodextrin (CD) modified PLGA nanoparticles loaded with paclitaxel (PTX PLGA/CD NPs) were prepared using the emulsification solvent evaporation method. The nanoparticles were characterized by particle size, zeta potential, encapsulation efficiency, infrared spectroscopy analysis and X-Ray diffraction (XRD). Then, drug release of the nanoparticles was evaluated via reverse dialysis method in vitro. Finally, the in vivo distribution fate and pharmacokinetic characteristics of the nanoparticles were assessed in mice and rats. Results: The average particle size, zeta potential, and encapsulation efficiency of PTX PLGA NPs were (163.57±2.07) nm, - (20.53±2.79) mV and (60.44±6.80)%. The average particle size, zeta potential, and encapsulation efficiency of PTX PLGA/CD NPs were (148.57±1.66) nm, - (11.42±0.84) mV and (85.70±2.06)%. In vitro release studies showed that PTX PLGA/CD NPs were released more slowly compared to PTX PLGA NPs under normal blood pH conditions, while PTX PLGA/CD NPs were released more completely under tumor site pH conditions. The modified PLGA nanocarrier (PLGA/CD NPs) increased drug residence time and accumulation than the plain PLGA nanocarrier (PLGA NPs) in vivo distribution. In addition, the elimination half-life, area under the drug-time curve, and maximum blood concentration of the nanoparticle group were higher than those of Taxol®, especially the PTX PLGA/CD NPs group, which was significantly different from Taxol® and plain nanoparticle groups (p<0.001). Conclusions: The 2-HP-β-CD modified PLGA nanoparticles prolonged circulation time and accumulation of the chemotherapy drug paclitaxel in vivo.

Paclitaxel controlled release system based on novel cerasome

Stabilized Liposomal Nanohybrid Cerasomes for Drug Delivery Applications

Modulation of Release of Paclitaxel from Composite Cerasomes.

A promising drug controlled-release system based on diacetylene/phospholipid polymerized vesicles.

Design and synthesis of lipidic organoalkoxysilanes for the self-assembly of liposomal nanohybrid cerasomes with controlled drug release properties.

Bridged bis(beta-cyclodextrin)s-based polysaccharide nanoparticles for controlled paclitaxel delivery

Cerasomal doxorubicin with long-term storage stability and controllable sustained release

Poly(ether-ester Anhydride)-Based Amphiphilic Block Copolymer Nanoparticle As Delivery Devices for Paclitaxel

Polydiacetylene vesicles as a novel drug sustained-release system.

Recent advances in liposomal nanohybrid cerasomes as promising drug nanocarriers.

Deoxycholic acid-modified chitooligosaccharide/mPEG-PDLLA mixed micelles loaded with paclitaxel for enhanced antitumor efficacy.

Delivery of paclitaxel by carboxymethyl chitosan-functionalized dendritic fibrous nano-silica: Fabrication, characterization, controlled release performance and pharmacokinetics

Photo-crosslinked Poly(ethylene Glycol)-B-poly(ϵ-caprolactone) Nanoparticles for Controllable Paclitaxel Release

Preparation of Copolymer Paclitaxel Covalently Linked Via a Disulfide Bond and Its Application on Controlled Drug Delivery.

Polymeric Micelles with Glycolipid-Like Structure and Multiple Hydrophobic Domains for Mediating Molecular Target Delivery of Paclitaxel.

Preparation and Characterization of Paclitaxel Delivery System Based on Semi-Solid Lipid Nanoparticles Coated with Poly (ethylene Glycol).

Nanoformulation of Paclitaxel: Exploring the Cyclodextrin / PLGA Nano Delivery Carrier to Slow Down Paclitaxel Release, Enhance Accumulation in Vivo

Engineering of dendritic mesoporous silica nanoparticles for efficient delivery of water-insoluble paclitaxel in cancer therapy

PLA-based Core-Shell Structure Stereocomplexed Nanoparticles with Enhanced Loading and Release Profile of Paclitaxel.

Liposomal Nanohybrid Cerasomes for Mitochondria-Targeted Drug Delivery

Micelles via self-assembly of amphiphilic beta-cyclodextrin block copolymers as drug carrier for cancer therapy